STUDresearch · Peptide
ACE-083
Also known as
ACE083 · local follistatin ligand trap · Acceleron ACE-083
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Local
IM into the studied muscle
Growth factors / muscle
Local intramuscular follistatin-based ligand trap — injected muscle, not a weekly systemic shop pin.
What people say
ACE-083 is a local intramuscular follistatin-based ligand trap. Phase 2 grew injected-muscle volume and failed function endpoints. It is not FLGR-242.
Doses people talk about
Local clinical milligrams do not convert into a shop pin.
How it may feel
No biohacker feel curve was found. Talk is trial volume-versus-function.
Phase 2 FSHD IM arms150–200 mg IM
Part 1 local IM every three weeks. Serum often undetectable. Not a DIY conversion.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- Felt effectsDiscussion centers on muscle size versus function; no consistent personal duration reported
Cycles people discuss
Public clocks are terminated neuromuscular Phase 2 periods, not a vendor peptide block.
Timing
Local IM design often left serum undetectable; that is not a 19-day FLGR number.
Stacks
Compared with FLGR / FS-344 / ACE-031, not stacked as a kitchen protocol.
Watch for
Volume without function is the outcome story.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No inspected public DIY-vial half-life for ACE-083.
Phase 1 local IM work often found no measurable serum drug. That is a distribution observation, not a consumer T½ table.
Terminated programs; local IM disease trials are not gray-vial PK.
- Statland et al. — Randomized phase 2 ACE-083 in FSHD (opens in a new tab)Phase 2 FSHD: muscle volume increased vs placebo; functional endpoints failed; anti-drug antibodies reported in the program summaries people paste alongside the CMT companion trial.Neuromuscular disease RCTs of a different construct than FLGR-242; programs terminated.
Felt duration people report
No biohacker feel curve was identified.
Talk is volume-vs-function trial outcomes.
Disease-program results are not n=1 gym diaries.
- Statland et al. — Randomized phase 2 ACE-083 in FSHD (opens in a new tab)Phase 2 FSHD: muscle volume increased vs placebo; functional endpoints failed; anti-drug antibodies reported in the program summaries people paste alongside the CMT companion trial.Neuromuscular disease RCTs of a different construct than FLGR-242; programs terminated.
What people say
- The community one-liner: “follistatin-class can grow a scan without growing a life.” forum
- Phase 2 FSHD / CMT: injected-muscle volume rose vs placebo in both programs. trial
- Then function endpoints failed (walk, stairs, falls, quality of life). Size without the job. trial
- Programs terminated. Not a current clinic product. trial
Doses people talk about
- Do not convert ACE-083 trial milligrams into FLGR 2.5–5 mg. forum
- No public DIY peptide-vial chart. forum
- Phase 1 healthy volunteers: local IM; serum drug often undetectable — the local-design pitch. trial
- Phase 2 FSHD Part 1: 150 mg or 200 mg IM into the studied muscle every three weeks. Not an FLGR conversion. trial
- Framing: Clinical IM trial dosing. Not an FLGR milligram chart. trial
How it may feel
- Now: Comparison object in FLGR skeptic threads. forum
- No biohacker diary culture with a verified bottle. forum
- Trial clock: repeated IM into the study muscle, not a weekday SubQ peptide. trial
- Stop: development stop, not a forum PCT. trial
Cycles people discuss
- Not a gray FS-344 camp. forum
- Phase 2 treatment periods in neuromuscular disease — not a 12-week vendor block. trial
- Programs ended after function failure. trial
Timing
- Do not paste 19-day FLGR numbers here. forum
- Local design: Phase 1 detected serum drug in only a small fraction of samples — the point was staying in the muscle. trial
- No inspected public DIY-vial T½. trial
More on what it is
- Why people talk about it: 2026 FLGR comparison pages paste it as “the last follistatin trap that actually got human RCTs.” forum
- Vs FLGR-242: FLGR is sold as systemic / albumin-bound. ACE-083 is the closest clinical readout for a follistatin-class trap and it is a different construct. forum
- What it is: A modified human follistatin engineered as a local ligand trap (myostatin, activin A, related brakes). Acceleron program ACE-083. Injected into a target muscle. trial
- How it works (plain): Trap the brakes locally so the injected muscle can grow. Design was local, not albumin-week systemic. trial
- Vs ACE-031: ACE-031 is an ActRIIB decoy with vascular AE lore. ACE-083 is a ligand trap. Same hallway, different door. trial
Stacks
- Compared with FLGR / FS-344 / ACE-031, not stacked. forum
- Not a Wolverine stack ingredient. forum
- Disease programs were monotherapy trial arms. trial
Storage notes
- Terminated clinic program, not BAC-water culture. forum
Watch for
- Not FLGR and not a current SKU. forum
- Anti-drug antibodies were common in the Phase 2 programs people paste (~39% and ~48%). trial
- Volume without function is the outcome story. trial
- Neuromuscular trial risk is not a gym SOP. trial
Evidence mix
More trial/lab tags than forum tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.